Pazopanib has been found to induce the accumulation of LC3II in bladder cancer (BC) cells and to increase the LC3II/LC3I ratio, accompanied by a progressive degradation of p62/SQSTM1. The gene discussed is SQSTM1; the disease is urinary bladder cancer.